- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
To Treat or Not to Treat: The Overdiagnosis Debate
Rapid advances in detection technology, coupled with an increased awareness about screening, have ignited a debate on overdiagnosis and overtreatment of precancerous lesions. Should physicians use their discretion and implement a "wait-and-watch" approach?
Early detection has long been seen as a powerful weapon in the battle against cancer. But some experts now see it as double-edged sword.
While it's clear that early-stage cancers are more treatable than late-stage ones, some leading cancer experts say that zealous screening and advanced diagnostic tools are finding ever-smaller abnormalities in prostate, breast, thyroid and other tissues. Many are being labeled cancer or precancer and treated aggressively, even though they may never have caused harm.
As a result, these experts say, many people may be undergoing surgery, radiation, chemotherapy and other treatments unnecessarily, sometimes with lifelong side effects.
Meanwhile, an estimated 586,000 Americans will die of cancer this year—many from very aggressive, fast-moving cancers that develop between screenings and spread too quickly to stop.
Read the commentary: http://on.wsj.com/1nWa7j7
Source: The Wall Street Journal
Other Resources: ASCO 2014 session: http://bit.ly/1uOBqjv
Source: Evidence-Based Oncology ASCO 2014 special issue
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
